Discover
COYA
Coya Therapeutics, Inc.
4.89
2 x 3.42
2 x 6.13
bid
ask
+
0.13
2.73%
2 @ 04:00 PM
4.89 +0.00 (0.00%)
| Ytd | -15.69% | |
| 1y | -14.81% |
4.71
day range
5.08
3.71
52 week range
7.75
| Open | 4.76 | Prev Close | 4.76 | Low | 4.71 | High | 5.08 | Mkt Cap | 114.71M |
| Vol | 403.46K | Avg Vol | 184.66K | EPS | -1.07 | P/E | N/A | Forward P/E | -4.25 |
| Beta | 0.61 | Short Ratio | 1.53 | Inst. Own | 19.97% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 4.62 | 200-d Avg | 4.79 | 1yr Est | 15.50 |
COYA News
benzinga.com
BTIG Reiterates Buy on Coya Therapeutics, Maintains $16 Price Target
BTIG analyst Thomas Shrader reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $
benzinga.com
Coya Therapeutics Enrolls 100th Participant In Phase 2/3 ALSTARS Trial Of COYA 302
Based on current screening and enrollment rates, topline data anticipated inearly Q2 2027Additional
businesswire.com
Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 f
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
benzinga.com
Coya Therapeutics Announces Publication Of Preclinical Results For COYA 303 In International Journal
Study results showed complementary immunomodulatory effects of COYA 303, a combination of proprietar
benzinga.com
Roth Capital Reiterates Buy on Coya Therapeutics, Maintains $12 Price Target
Roth Capital analyst Boobalan Pachaiyappan reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy